Icatibant Acetate

Icatibant Acetate is a selective competitive antagonist for the bradykinin B2 receptor. It is indicated for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare disorder resulting in periodic attacks of acute edema. It is characterized by a deficiency of functional C1 esterase inhibitor that leads to the overproduction of bradykinin, which triggers vasodilation, vascular permeability, and edema. Icatibant Acetate inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.